Skip to main content
Signal8
Launch Terminal

Microbot Medical Inc. (MBOT)

Microbot Medical Inc. operates as a pre-clinical stage medical device company, concentrating its efforts on the research, design, and development of robotic instruments for endoluminal surgery, specifically targeting the field of minimally invasive procedures. Leveraging its proprietary micro-robotic technologies, which include ViRob, TipCAT, CardioSert, and Liberty, the company is actively developing several key products. These include a Self-Cleaning Shunt intended for the treatment of hydrocephalus and normal pressure hydrocephalus, as well as a single-use robotic system designed for various endovascular interventional applications. Additionally, Microbot Medical maintains a robust, multi-generational product pipeline. Its global intellectual property portfolio is substantial, encompassing 42 granted or allowed patents and an additional 23 patent applications currently under review. The company also benefits from a strategic collaboration agreement with Stryker Corporation, focusing on joint technology development. Established in 2010, Microbot Medical Inc. is headquartered in Hingham, Massachusetts.

Sector: Surgical & Medical Instruments & Apparatus

Industry: Medical - Devices

Microbot Medical Inc. logo

Microbot Medical Inc.

NASDAQ:MBOTHealthcare
-2.68%$1.09
AH$1.09-0.02%vs close
Mkt Cap$73.21M
Float67.03M
O/S67.16M
Vol
$ Vol
RVOL
Inst Own16.9%
Earnings
Dilution
Microbot Medical Inc. logoNASDAQ:MBOT$1.09-2.68%
Phase Distribution
11 lead-sponsored trials·0 active·6 completed
Phase 13
Phase 1/22
Phase 22
Not applicable4
Status Overview
Completed6
Stopped5

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Status
Phase
  • Phase 2
    Terminated

    Study of Human Central Nervous System (CNS) Stem Cell Transplantation in Cervical Spinal Cord Injury

    HuCNS-SC cells

    Cervical Spinal Cord Injury, Spine Injury +1

    Enrollment
    31
    Start
    Oct 2014
    Primary Completion
    May 2016
    Completion
    May 2016
    NCT02163876
  • Phase 2
    Terminated

    Study of HUCNS-SC Subretinal Transplantation in Subjects With GA of AMD

    HuCNS-SC sub-retinal transplantation

    Age-Related Macular Degeneration

    Enrollment
    3
    Start
    Jun 2015
    Primary Completion
    May 2016
    Completion
    May 2016
    NCT02467634
  • Phase 1/2
    Completed

    Study of Human Central Nervous System Stem Cells (HuCNS-SC) in Patients With Thoracic Spinal Cord Injury

    HuCNS-SC cells

    Thoracic Spinal Cord Injury, Spinal Cord Injury +2

    Enrollment
    12
    Start
    Mar 2011
    Primary Completion
    Apr 2015
    Completion
    Apr 2015
    NCT01321333
  • Phase 1/2
    Completed

    Study of Human Central Nervous System Stem Cells (HuCNS-SC) in Age-Related Macular Degeneration (AMD)

    HuCNS-SC cells

    Age Related Macular Degeneration, Macular Degeneration +1

    Enrollment
    15
    Start
    Jun 2012
    Primary Completion
    Jun 2015
    Completion
    Jun 2015
    NCT01632527
  • Phase 1
    Completed

    Study of HuCNS-SC Cells in Patients With Infantile or Late Infantile Neuronal Ceroid Lipofuscinosis (NCL)

    Medication to suppress the immune system

    Neuronal Ceroid Lipofuscinosis

    Enrollment
    6
    Start
    May 2006
    Primary Completion
    Feb 2009
    Completion
    Sep 2009
    NCT00337636
  • Phase 1
    Completed

    Study of Human Central Nervous System (CNS) Stem Cells Transplantation in Pelizaeus-Merzbacher Disease (PMD) Subjects

    HuCNS-SC cells

    Pelizaeus-Merzbacher Disease

    Enrollment
    4
    Start
    Nov 2009
    Primary Completion
    Oct 2012
    Completion
    Dec 2012
    NCT01005004
  • Phase 1
    Withdrawn

    Safety and Efficacy Study of HuCNS-SC in Subjects With Neuronal Ceroid Lipofuscinosis

    HuCNS-SC

    Neuronal Ceroid Lipofuscinosis

    Enrollment
    0
    Start
    Nov 2010
    Primary Completion
    Apr 2011
    Completion
    Apr 2011
    NCT01238315
  • Observational
    Completed

    Long-Term Follow-Up Study of Human Stem Cells Transplanted in Subjects With Connatal Pelizaeus-Merzbacher Disease (PMD)

    HuCNS-SC transplant in the lead-in phase

    Pelizaeus-Merzbacher Disease, PMD

    Enrollment
    4
    Start
    Jun 2011
    Primary Completion
    Mar 2016
    Completion
    Mar 2016
    NCT01391637
  • Observational
    Terminated

    Long-Term Follow-Up of Transplanted Human Central Nervous System Stem Cells (HuCNS-SC) in Spinal Cord Trauma Subjects

    Observation

    Spinal Cord Injury

    Enrollment
    12
    Start
    Nov 2012
    Primary Completion
    May 2016
    Completion
    May 2016
    NCT01725880
  • Observational
    Terminated

    Long-Term Follow-up Safety Study of Human Central Nervous System Stem Cells in Subjects With Geographic Atrophy of Age-Related Macular Degeneration

    Human Central Nervous System Stem Cells

    Age-Related Macular Degeneration, Geographic Atrophy

    Enrollment
    8
    Start
    Apr 2014
    Primary Completion
    May 2016
    Completion
    May 2016
    NCT02137915
  • Not applicable
    Completed

    Assessment of Clin. Capabilities of LIBERTY® Endovascular Robotic System's Performance & Safety in Periph. Vasc. Interv.

    The LIBERTY® Robotic System

    Peripheral Vascular Interventions

    Enrollment
    20
    Start
    Jul 2024
    Primary Completion
    Oct 2024
    Completion
    Oct 2024
    NCT06141694
Search ClinicalTrials.gov for “Microbot Medical”